Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group

about

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group

Item

http://www.wikidata.org/entity/Q58754638

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Initiation and maintenance of ...... the UK Retinal Outcomes Group

@en

Initiation and maintenance of ...... the UK Retinal Outcomes Group

@nl

type

Item

label

Initiation and maintenance of ...... the UK Retinal Outcomes Group

@en

Initiation and maintenance of ...... the UK Retinal Outcomes Group

@nl

prefLabel

Initiation and maintenance of ...... the UK Retinal Outcomes Group

@en

Initiation and maintenance of ...... the UK Retinal Outcomes Group

@nl

P1476

Initiation and maintenance of ...... the UK Retinal Outcomes Group

@en

P2093

Athanasios Vardarinos

http://www.w3.org/2001/XMLSchema#string

Bushra Mushtaq

http://www.w3.org/2001/XMLSchema#string

Hemal Mehta

http://www.w3.org/2001/XMLSchema#string

Konstantinos Balaskas

http://www.w3.org/2001/XMLSchema#string

Louise Downey

http://www.w3.org/2001/XMLSchema#string

Markus Groppe

http://www.w3.org/2001/XMLSchema#string

Philip Severn

http://www.w3.org/2001/XMLSchema#string

Quresh Mohamed

http://www.w3.org/2001/XMLSchema#string

Saad Younis

http://www.w3.org/2001/XMLSchema#string

Sajjad Mahmood

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Defining response to anti-VEGF therapies in neovascular AMD

Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study.

24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.

Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA

Severity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye Study.

Health professionals' and service users' perspectives of shared care for monitoring wet age-related macular degeneration: a qualitative study alongside the ECHoES trial.

Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.

Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care.

The estimated prevalence and incidence of late stage age related macular degeneration in the UK

P304

1731-1740

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2147/OPTH.S174560

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30237693

http://www.w3.org/2001/XMLSchema#string

P932

6136415

http://www.w3.org/2001/XMLSchema#string